N. P. Christy, M.D.; J. C. Shaver, M.D.; M. S. Roginsky, M.D.
This content is PDF only. Please click on the PDF icon to access.
Two 3-μC doses of 4-C14-estradiol-17 beta were administered intravenously to each of 6 patients with normal hepatic, cardiac, and renal function, 2 patients with viral hepatitis, and 2 patients with Laennec's cirrhosis. Plasma samples were taken at 15, 30, 60, 120, and 240 minutes after injection, extracted with chloroform (85 to 99% recovery of added tritiated estradiol), and assayed for C14 radioactivity in a liquid scintillation counter. Plasma half-times of total administered radioactivity were calculated from the disappearance curves obtained; these showed no significant differences in hepatic disease without ascites (78 to 155 minutes) from normal values (105 to 145
Christy NP, Shaver JC, Roginsky MS. Clearance from Plasma of 4-C14-Estradiol-17 Beta in Patients with Hepatic Disease.. Ann Intern Med. ;58:724. doi: 10.7326/0003-4819-58-4-724_1
Download citation file:
Published: Ann Intern Med. 1963;58(4):724.
Gastroenterology/Hepatology, Liver Disease.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use